AbbVie Appears to Win Most of $480 Million It Sought From Takeda

AbbVie Endocrine Inc. won a court ruling in Delaware on Tuesday that appeared to award the drug giant most of the $480.6 million it sought over Takeda Pharmacetical Co. Ltd’s breaches of a supply agreement involving the cancer drug Lupron.

Vice Chancellor Sam Glasscock III largely accepted AbbVie’s method of calculating the damages amount, the only issue that remained in dispute after he ruled in 2021 that Takeda was liable for breaching their supply agreements. The judge presided over a second trial, focused solely on damages, in January. Takeda had argued for damages of only $295 million.

Glasscock, writing for ...